Inside One Company’s Quest to Develop a COVID-19 Antibody Treatment: A Q&A with Regeneron’s George Yancopoulos

While teams race to develop a vaccine, Regeneron’s treatment would use antibodies to give patients short-term immunity.

By Dan Hurley
Apr 8, 2020 3:00 PMNov 3, 2020 5:05 PM
Coronavirus on a dark blue background with purple effect
(Credit: Andrii Vodolazhskyi/Shutterstock)

Newsletter

Sign up for our email newsletter for the latest science news
 

When I read back in mid-March that the biotech firm Regeneron had isolated “hundreds of neutralizing antibodies against the SARS-CoV-2 virus,” I thought it sounded crazy. Antibodies, after all, are the immune system’s hound dogs, trained to recognize and attack any viral or microbial invader.

Even though the roughly 30-year-old company has previously developed a three-antibody drug to treat Ebola, I couldn’t understand how so many potential treatments could be isolated in a matter of weeks by a single entity. So I hopped on the phone March 23 with George Yancopoulos, the company’s co-founder, president and chief scientific officer. He spoke from his car, and I hoped he was driving slower than he talked. This conversation has been lightly edited for brevity.

0 free articles left
Want More? Get unlimited access for as low as $1.99/month

Already a subscriber?

Register or Log In

0 free articlesSubscribe
Discover Magazine Logo
Want more?

Keep reading for as low as $1.99!

Subscribe

Already a subscriber?

Register or Log In

Stay Curious

Sign up for our weekly newsletter and unlock one more article for free.

 

View our Privacy Policy


Want more?
Keep reading for as low as $1.99!


Log In or Register

Already a subscriber?
Find my Subscription

More From Discover
Recommendations From Our Store
Shop Now
Stay Curious
Join
Our List

Sign up for our weekly science updates.

 
Subscribe
To The Magazine

Save up to 40% off the cover price when you subscribe to Discover magazine.

Copyright © 2023 Kalmbach Media Co.